Opinion on Respiratory in Netherlands

Select information type

Refine your search

search
Search tips

by industry

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Crucell: failed vaccine disappoints

Crucell has halted development of Aerugen, its late-stage vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, following disappointing phase III trial results. Although this is something of a setback for vaccine development within the field of cystic fibrosis, other efforts focusing on ion channel therapy still provide a glimmer of hope.

Published By Datamonitor
19 Jul 2006
CommentWire
CommentWire

Merck: generic Singulair threat becomes reality

As anticipated, Merck is about to face a significant decrease in revenue as the first generic versions of its blockbuster Singulair reach the US market. Although Merck's strong pipeline is aimed at offsetting the impact of generic erosion, little can be done in the immediate future to stem this loss.

Published By Datamonitor
06 Aug 2012

« | 1 | » »|

No help is available.